Drug Trial Radar · NCT00049517
Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With AML Leukemia
Last checked: Nov 20, 2026Latest source record: Jun 15, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
657
Actual
Start
Dec 19, 2002
Primary completion
Mar 2009
Study completion Dec 2019
Sponsor
- Lead sponsor
- Eastern Cooperative Oncology GroupResearch network
- Sponsor type
- Research network
- Collaborators
- National Cancer Institute (NCI)
- First posted
- Jan 27, 2003
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 16 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
RATIONALE: Giving combination chemotherapy before a stem cell transplant helps stop the growth of cancer cells. It also helps stop the patient's immune system from rejecting the transplanted stem cells. When the healthy stem cells are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. If the patient's stem cells are to be transplanted, the patient is also treated with a monoclonal antibody, such as gemtuzumab ozogamicin, to kill any remaining cancer cells or deliver cancer-killing substances to them without harming normal cells. It is not yet known whether combination chemotherapy is more effective with or without gemtuzumab ozogamicin followed by stem cell transplant in treating acute myeloid leukemia. PURPOSE: This randomized phase III trial is studying combination chemotherapy, gemtuzumab ozogamicin, and stem cell transplant to see how well they work compared to combination chemotherapy and peripheral stem cell transplant alone in treating patients with acute myeloid leukemia.
Conditions
- Leukemia
Interventions
sargramostimBiological
Given IV or as an injection
busulfanDrug
Given IV
cyclophosphamideDrug
Given IV
cytarabineDrug
Given as a continuous infusion
gemtuzumab ozogamicin (GO)Drug
Given IV
DaunorubicinDrug
Given intravenously daily for 3 days at a dose of either 45 or 90 mg/m2.
Autologous HCTProcedure
Autologous hematopoietic cell transplantation
Allogeneic HCTProcedure
Allogeneic hematopoietic cell transplantation
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Survival (Induction Phase)Time frame: Assessed during the first 4 months, then at least every three months for 2 years. then every six months until 5 years after study entry and every 12 months thereafter.
- Disease-free Survival (Consolidation Phase)Time frame: Assessed during the first 4 months, then at least every three months for 2 years. then every six months until five years after study entry, and every 12 months thereafter.
Locations
99 sites in 2 countries. Site status is shown where the registry gives one.
Lurleen Wallace Comprehensive Cancer at University of Alabama - Birmingham
Birmingham, Alabama
Mayo Clinic Scottsdale
Scottsdale, Arizona
Aurora Presbyterian Hospital
Aurora, Colorado
Penrose Cancer Center at Penrose Hospital
Colorado Springs, Colorado
St. Anthony Central Hospital
Denver, Colorado
Porter Adventist Hospital
Denver, Colorado
Presbyterian - St. Luke's Medical Center
Denver, Colorado
St. Joseph Hospital
Denver, Colorado
Rose Medical Center
Denver, Colorado
CCOP - Colorado Cancer Research Program
Denver, Colorado
Swedish Medical Center
Englewood, Colorado
St. Mary's Regional Cancer Center at St. Mary's Hospital and Medical Center
Grand Junction, Colorado
North Colorado Medical Center
Greeley, Colorado
Sky Ridge Medical Center
Lone Tree, Colorado
Hope Cancer Care Center at Longmont United Hospital
Longmont, Colorado
McKee Medical Center
Loveland, Colorado
St. Mary - Corwin Regional Medical Center
Pueblo, Colorado
North Suburban Medical Center
Thornton, Colorado
Exempla Lutheran Medical Center
Wheat Ridge, Colorado
Eugene M. and Christine E. Lynn Cancer Institute at Boca Raton Community Hospital - West
Boca Raton, Florida
Eugene M. and Christine E. Lynn Cancer Institute at Boca Raton Community Hospital - Main Campus
Boca Raton, Florida
University of Florida Shands Cancer Center
Gainesville, Florida
University of Miami Sylvester Comprehensive Cancer Center - Miami
Miami, Florida
Winship Cancer Institute of Emory University
Atlanta, Georgia
Robert H. Lurie Comprehensive Cancer Center at Northwestern University
Chicago, Illinois
Hematology and Oncology Associates
Chicago, Illinois
Evanston Northwestern Healthcare - Evanston Hospital
Evanston, Illinois
Midwest Center for Hematology/Oncology
Joliet, Illinois
Joliet Oncology-Hematology Associates, Limited - West
Joliet, Illinois
North Shore Oncology and Hematology Associates, Limited - Libertyville
Libertyville, Illinois
La Grange Oncology Associates - Geneva
Naperville, Illinois
Cancer Care and Hematology Specialists of Chicagoland - Niles
Niles, Illinois
Advocate Lutheran General Cancer Care Center
Park Ridge, Illinois
Hematology Oncology Associates - Skokie
Skokie, Illinois
Carle Cancer Center at Carle Foundation Hospital
Urbana, Illinois
CCOP - Carle Cancer Center
Urbana, Illinois
Fort Wayne Medical Oncology and Hematology
Fort Wayne, Indiana
Indiana University Melvin and Bren Simon Cancer Center
Indianapolis, Indiana
Tufts-NEMC Cancer Center
Boston, Massachusetts
Borgess Medical Center
Kalamazoo, Michigan
Showing 40 of 99 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.